reducing cardiovascular risk: an emphasis on rosuvastatin
Clicks: 176
ID: 200220
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
3.9
/100
13 views
13 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Rosuvastatin is one of the most frequently prescribed drugs for primary and secondary prevention of myocardial infarction and stroke. The present article deals with the main studies confirming the effectiveness of rosuvastatin in patients with different cardiovascular risks.
| Reference Key |
g.s.2017reducing
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Anikin G.S.;Storozhuk I.K.;Filyazova Ya.Yu. |
| Journal | pediatric urology case reports |
| Year | 2017 |
| DOI |
10.26442/2075-082X_14.4.50-54
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.